Astera Labs vs. Applied Materials: Which Technology Stock Is a Better Buy in 2026?

Applied Materials is favored over Astera Labs for long-term investors, combining a lower 26.3x forward P/E and 12.2x P/S ratio with expected FY2026 sales growth of 21% to $34.3 billion and net-income growth of 50%. Astera delivered FY2025 revenue growth of roughly 115% to $853 million and reported Q2 2026 revenue of $392.4 million, up 104% year over year, but trades at elevated 43.9x forward P/E and 43.0x P/S multiples. Astera's investment case is also tempered by customer concentration, with one customer accounting for more than 70% of FY2025 revenue, while both companies remain exposed to AI-capex cycles, supply-chain constraints, and trade or export restrictions.

Analysis

The relevant distinction is not simply growth versus value: ALAB monetizes the AI cluster architecture transition at the rack level, while AMAT monetizes the capital-intensity required to expand leading-edge logic, advanced packaging, and memory supply. ALAB's revenue can compound faster when new interconnect standards or rack designs are adopted, but its economics are exposed to design-win timing and customer-specific inventory corrections; AMAT's earnings sensitivity is broader but delayed, arriving through foundry and memory capex budgets. The cited comparison also conflates AMAT's equipment competitive set with chip suppliers: the more relevant public comparables for AMAT are LRCX, KLAC and ASML, not AVGO or MRVL.

For the next 1-3 months, ALAB's multiple leaves little room for merely in-line execution: any sequential deceleration, weaker backlog conversion, or evidence that a leading hyperscaler is dual-sourcing connectivity could cause a disproportionate derating. Conversely, the key upside catalyst is proof that revenue is diversifying faster than investors expect, particularly through Ethernet or non-anchor-customer design wins. AMAT has a cleaner risk/reward setup if AI-led wafer-fab equipment demand broadens beyond a small number of leading-edge customers, but China restrictions or a memory-capex pause would likely pressure estimates before reported revenue materially declines.

The contrarian point is that connectivity is increasingly a system bottleneck, not a peripheral component; ALAB could sustain premium economics if scale-out architectures require materially more retimers, switches, and fabric-management content per GPU cluster. Yet this is precisely where large incumbents AVGO and MRVL have strategic incentive and distribution advantages, making ALAB's valuation dependent on sustained product differentiation rather than the headline AI spending cycle. AMAT is the preferable core exposure, but a long AMAT/short ALAB relative trade should only be sized after confirming current valuation dispersion, short interest, and upcoming earnings dates.

Key Decisions for Investors

• Establish a 6-12 month long AMAT position versus a semiconductor-equipment basket (LRCX, KLAC, ASML) only if AMAT continues to trade at a discount on forward EPS growth; thesis is operating leverage from advanced logic/packaging demand. Exit on a material WFE guidance cut or incremental China-related export restriction that lowers fiscal-year estimates.
• Use ALAB as an event-driven, not core, long: initiate only after a post-earnings pullback or when management demonstrates lower customer concentration and sustained sequential revenue growth. A position requires a defined stop on guidance deceleration, because premium-sales-multiple compression can outweigh continued topline growth.
• Monitor AVGO and MRVL product commentary for PCIe, Ethernet switching, and custom silicon attach-rate gains over the next two earnings cycles. Evidence of share capture or aggressive pricing is a negative read-through for ALAB and would support reducing exposure rather than adding.
• For a relative-value expression, watch long AMAT/short ALAB over 3-6 months if ALAB's premium remains elevated while AMAT estimates rise; target is convergence through AMAT estimate revisions rather than an outright AI demand slowdown. Do not execute without current beta, borrow cost, and factor-exposure checks.